Today: 1 July 2026
Browse Category

Cryptocurrency 20 January 2026 - 21 January 2026

Russia’s new crypto crackdown: $128,000 fines proposed for illegal mining in banned regions

Russia’s new crypto crackdown: $128,000 fines proposed for illegal mining in banned regions

Russian lawmakers introduced a bill proposing fines for illegal cryptocurrency mining and permitting the confiscation of mining gear, targeting an industry known to put pressure on local power supplies. The draft arrives amid Russia’s push to tighten regional bans and pull more miners under official regulation. Mining was legalized in 2024 with a registry system, yet from January 2025, authorities rolled out broad restrictions across several regions, including outright bans until March 2031 in some areas and seasonal curbs in others.
21 January 2026
Russia moves to slap illegal crypto miners with fines up to 10 million rubles

Russia moves to slap illegal crypto miners with fines up to 10 million rubles

Russian lawmakers have put forward a bill proposing fresh administrative penalties for violations of the country’s cryptocurrency mining regulations. The draft includes fines reaching 10 million roubles for companies caught repeating offences, along with the potential seizure of mining hardware. The draft arrives amid Russia’s crackdown on a sector boosted by low-cost electricity, following government bans on mining in multiple regions due to reported power shortages and strain on the grid.
21 January 2026
IREN stock drops 6% after-hours as Bitcoin slides and tariff jitters hit risk trades

IREN stock drops 6% after-hours as Bitcoin slides and tariff jitters hit risk trades

New York, January 20, 2026, 18:02 EST — After-hours Nasdaq-listed IREN Limited shares dropped 6.2%, closing at $54.26 in after-hours trading Tuesday. The stock fluctuated between $52.01 and $57.63, with roughly 45 million shares changing hands. Bitcoin slipped 4.7%, dragging miners Marathon Digital, Riot Platforms, and CleanSpark down by 4.6% to 8.8%.
21 January 2026
···
Vanguard’s $505M Strategy Stake Puts Bitcoin-Proxy Stock MSTR Back in Play

Vanguard’s $505M Strategy Stake Puts Bitcoin-Proxy Stock MSTR Back in Play

Vanguard’s U.S. mid-cap index fund has made its first disclosed purchase of Strategy Inc, acquiring around 2.91 million shares valued at approximately $505 million, Odaily Planet Daily reported on Binance Square. Strategy plans to release its fourth-quarter earnings on Feb. 5 and currently holds 687,410 bitcoin, worth about $66.5 billion. The disclosure is drawing attention since Vanguard ranks among the largest money managers worldwide. The firm reported managing $12 trillion in assets globally as of Nov. 30, 2025, so even a $500 million stake barely registers on its books.
20 January 2026
···
Hoskinson vs Garlinghouse Gets Ugly as U.S. CLARITY Crypto Bill Splits Industry

Hoskinson vs Garlinghouse Gets Ugly as U.S. CLARITY Crypto Bill Splits Industry

Cardano founder Charles Hoskinson slammed Ripple CEO Brad Garlinghouse over the latest draft of the U.S. “CLARITY” crypto bill, urging the industry to “fight for what’s right” instead of settling for a bank-friendly compromise. Garlinghouse had praised lawmakers, calling the frameworks “workable” and insisting “clarity beats chaos.” Ripple has yet to comment on the criticism, Benzinga reported. The Senate Banking Committee has postponed its planned “markup” — the session to debate and vote on bill amendments — following Coinbase CEO Brian Armstrong’s statement that his company cannot back the current version. Armstrong declared, “We’d rather have no bill than a bad bill.” Committee chairman Tim Scott responded, saying “everyone remains at the table working in good faith.”
20 January 2026
··
1 … 34 35 36 37 38 … 106

Stock Market Today

  • Kymera Therapeutics (KYMR) up 51% YTD as atopic dermatitis drug hits milestones
    July 1, 2026, 2:57 PM EDT. Kymera Therapeutics (KYMR) is up nearly 51% this year, way ahead of the sector's 6.4%. The stock's gain is tied to progress on KT-621, an oral STAT6 degrader for atopic dermatitis and asthma. Kymera wrapped phase IIb enrollment in the BROADEN2 AD trial six months early, aiming to have the pivotal readout by late 2026. Earlier, phase Ib data showed strong STAT6 knockdown and safety. The FDA put KT-621 on Fast Track for moderate-to-severe AD and eosinophilic asthma. Separately, trials for KT-485, in partnership with Sanofi, led to a $20 million milestone, and Kymera is still developing KT-579. Its alliances with Sanofi and Gilead are part of the company's long-term plans.
Go toTop